Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Classificação em ações
#4949
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Preço da ação
$2.47
Valor de mercado
$2.95B
Variação (1 dia)
0.18%
Variação (1 ano)
-14.53%
País
CN
Negociar Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Categoria
Healthcare
Lucros da Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Lucros em Jun 2026 TTM: $450.70M
De acordo com os últimos relatórios financeiros da Jilin Aodong Pharmaceutical Group Co., Ltd., os ganhos atuais da empresa são de $450.70M. Em 2023, a empresa teve ganhos de $211.93M, uma diminuição em relação a aos ganhos de 2022, que foram de $249.47M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Jilin Aodong Pharmaceutical Group Co., Ltd. de 2000 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $450.70M | 116.23% |
| 2024 | $208.44M | -1.65% |
| 2023 | $211.93M | -15.05% |
| 2022 | $249.47M | -10.25% |
| 2021 | $277.96M | 5.78% |
| 2020 | $262.76M | 23.65% |
| 2019 | $212.51M | 47.80% |
| 2018 | $143.78M | -51.61% |
| 2017 | $297.11M | 18.54% |
| 2016 | $250.63M | -39.05% |
| 2015 | $411.21M | 71.49% |
| 2014 | $239.79M | 22.14% |
| 2013 | $196.32M | 79.35% |
| 2012 | $109.46M | -71.97% |
| 2011 | $390.52M | 99.92% |
| 2010 | $195.34M | -5.51% |
| 2009 | $206.72M | 55.20% |
| 2008 | $133.20M | -52.18% |
| 2007 | $278.56M | 315.81% |
| 2006 | $66.99M | 289.48% |
| 2005 | $17.20M | -21.22% |
| 2004 | $21.83M | 20.73% |
| 2003 | $18.09M | 43.68% |
| 2002 | $12.59M | 67.81% |
| 2001 | $7.50M | -36.78% |
| 2000 | $11.87M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 291.51% |
IN
|
